Send us Feedback

CVS Caremark Corporation (CVS)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

CVS » Topics » Supplemental Unaudited Information

This excerpt taken from the CVS 8-K filed May 5, 2009.

Supplemental Unaudited Information

The Company evaluates segment performance based on net revenue, gross profit and operating profit before the effect of discontinued operations and certain intersegment activities and charges. Following is a reconciliation of the Company’s business segments to the accompanying consolidated financial statements:

 

In millions

    Pharmacy Services
Segment(1)(2)		    Retail Pharmacy
Segment(1)		    Intersegment
Eliminations(1)(3)		     Consolidated
Totals(1)

Fiscal Quarter Ended

           

March 31, 2009:

           

Net revenues

    $ 11,534.8    $ 13,496.9    $ (1,637.8 )   $ 23,393.9

Gross profit

      791.8      3,956.2      —         4,748.0

Operating profit

      485.8      891.4      —         1,377.2

March 29, 2008:

           

Net revenues

    $ 10,764.7    $ 11,845.6    $ (1,284.3 )   $ 21,326.0

Gross profit

      788.0      3,505.0      —         4,293.0

Operating profit

      530.0      840.1      —         1,370.1

 

(1) On December 23, 2008, our Board of Directors approved a change in our fiscal year end from the Saturday nearest December 31 of each year to December 31 of each year to better reflect our position in the health care, rather than the retail, industry. As you review our operating performance, please consider that the fiscal quarter ended March 31, 2009 and March 29, 2008 include 90 days and 91 days, respectively.

 

(2) Net revenues of the Pharmacy Services Segment include approximately $1,667.9 million and $1,664.9 million of Retail Co-payments for the first quarter of 2009 and 2008, respectively.

 

(3) Intersegment eliminations relate to intersegment revenues and accounts receivables that occur when a Pharmacy Services Segment customer uses a Retail Pharmacy Segment store to purchase covered products. When this occurs, both segments record the revenue on a standalone basis.

This excerpt taken from the CVS 8-K filed May 1, 2008.

Supplemental Unaudited Information

The Company evaluates segment performance based on net revenue, gross profit and operating profit before the effect of non-recurring charges and gains and certain intersegment activities and charges. Following is a reconciliation of the Company’s business segments to the accompanying consolidated financial statements:

 

In millions

    Retail Pharmacy
Segment		    Pharmacy Services
Segment(1)		    Intersegment
Eliminations (2)		     Consolidated
Totals

13 Weeks Ended:

           

March 29, 2008:

           

Net revenues

    $ 11,845.6    $ 10,764.7    $ (1,284.3 )   $ 21,326.0

Gross profit

      3,505.0      788.0      —         4,293.0

Operating profit

      840.1      530.0      —         1,370.1

March 31, 2007:

           

Net revenues

    $ 11,239.2    $ 2,110.3    $ (160.9 )   $ 13,188.6

Gross profit

      3,105.7      197.5      —         3,303.2

Operating profit

      625.9      110.6      —         736.5

 

(1) Net revenues of the Pharmacy Services Segment include approximately $1,664.9 million and $156.0 million of Retail Co-payments for the thirteen weeks ended March 29, 2008 and March 31, 2007, respectively.
(2) Intersegment eliminations relate to intersegment revenues that occur when a Pharmacy Services Segment customer uses a Retail Pharmacy Segment store to purchase covered products. When this occurs, both segments record the revenue on a standalone basis.

EXCERPTS ON THIS PAGE:

8-K
May 5, 2009
8-K
May 1, 2008

RELATED TOPICS for CVS:

"Supplemental Unaudited Information" elsewhere:

Wal-Mart (WMT)
BRAZILIAN DISTRIBUTION CO COMPANHIA BRASILEIRA DE DISTR CBD (CBD)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki